Back

REACT-1 round 13 interim report: acceleration of SARS-CoV-2 Delta epidemic in the community in England during late June and early July 2021

Riley, S.; Eales, O.; Haw, D.; Wang, H.; Walters, C. E.; Ainslie, K. E. C.; Atchinson, C.; Fronterre, C.; Diggle, P. J.; Ashby, D.; Donnelly, C. A.; Barclay, W.; Cooke, G.; Ward, H.; Darzi, A.; Elliott, P.

2021-07-08 infectious diseases
10.1101/2021.07.08.21260185 medRxiv
Show abstract

BackgroundDespite high levels of vaccination in the adult population, cases of COVID-19 have risen exponentially in England since the start of May 2021 driven by the Delta variant. However, with far fewer hospitalisations and deaths per case during the recent growth in cases compared with 2020, it is intended that all remaining social distancing legislation in England will be removed from 19 July 2021. MethodsWe report interim results from round 13 of the REal-time Assessment of Community Transmission-1 (REACT-1) study in which a cross-sectional sample of the population of England was asked to provide a throat and nose swab for RT-PCR and to answer a questionnaire. Data collection for this report (round 13 interim) was from 24 June to 5 July 2021. ResultsIn round 13 interim, we found 237 positives from 47,729 swabs giving a weighted prevalence of 0.59% (0.51%, 0.68%) which was approximately four-fold higher compared with round 12 at 0.15% (0.12%, 0.18%). This resulted from continued exponential growth in prevalence with an average doubling time of 15 (13, 17) days between round 12 and round 13. However, during the recent period of round 13 interim only, we observed a shorter doubling time of 6.1 (4.0, 12) days with a corresponding R number of 1.87 (1.40, 2.45). There were substantial increases in all age groups under the age of 75 years, and especially at younger ages, with the highest prevalence in 13 to 17 year olds at 1.33% (0.97%, 1.82%) and in 18 to 24 years olds at 1.40% (0.89%, 2.18%). Infections have increased in all regions with the largest increase in London where prevalence increased more than eight-fold from 0.13% (0.08%, 0.20%) in round 12 to 1.08% (0.79%, 1.47%) in round 13 interim. Overall, prevalence was over 3 times higher in the unvaccinated compared with those reporting two doses of vaccine in both round 12 and round 13 interim, although there was a similar proportional increase in prevalence in vaccinated and unvaccinated individuals between the two rounds. DiscussionWe are entering a critical period with a number of important competing processes: continued vaccination rollout to the whole adult population in England, increased natural immunity through infection, reduced social mixing of children during school holidays, increased proportion of mixing occurring outdoors during summer, the intended full opening of hospitality and entertainment and cessation of mandated social distancing and mask wearing. Surveillance programmes are essential during this next phase of the epidemic to provide clear evidence to the government and the public on the levels and trends in prevalence of infections and their relationship to vaccine coverage, hospitalisations, deaths and Long COVID.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
The Lancet Infectious Diseases
71 papers in training set
Top 0.1%
14.3%
2
Eurosurveillance
80 papers in training set
Top 0.1%
13.9%
3
Journal of Infection
71 papers in training set
Top 0.1%
8.1%
4
Nature Communications
4913 papers in training set
Top 24%
8.0%
5
BMJ Open
554 papers in training set
Top 4%
6.2%
50% of probability mass above
6
The Lancet Regional Health - Europe
32 papers in training set
Top 0.1%
4.7%
7
PLOS Medicine
98 papers in training set
Top 1.0%
3.8%
8
eClinicalMedicine
55 papers in training set
Top 0.1%
3.8%
9
BMC Medicine
163 papers in training set
Top 1%
3.8%
10
Science
429 papers in training set
Top 9%
3.5%
11
BMC Infectious Diseases
118 papers in training set
Top 2%
2.5%
12
The Lancet
16 papers in training set
Top 0.2%
2.0%
13
Emerging Infectious Diseases
103 papers in training set
Top 1%
2.0%
14
PLOS ONE
4510 papers in training set
Top 49%
2.0%
15
BMC Public Health
147 papers in training set
Top 3%
1.7%
16
International Journal of Epidemiology
74 papers in training set
Top 1%
1.6%
17
Wellcome Open Research
57 papers in training set
Top 1%
1.2%
18
BMJ
49 papers in training set
Top 1.0%
0.9%
19
The Lancet Healthy Longevity
11 papers in training set
Top 0.1%
0.9%
20
Journal of Epidemiology and Community Health
32 papers in training set
Top 0.5%
0.9%
21
The Lancet Respiratory Medicine
17 papers in training set
Top 0.2%
0.8%
22
New England Journal of Medicine
50 papers in training set
Top 0.9%
0.7%
23
The Lancet Public Health
20 papers in training set
Top 0.9%
0.6%
24
Thorax
32 papers in training set
Top 1.0%
0.6%